Eisai Company, Ltd. (ESALY.PK) Receives Approval for a New Oral Jelly Formulation of Aricept(R) for the Treatment of Alzheimer's Disease in Japan  
8/4/2009 9:53:24 AM

Tokyo, July 22, 2009 (JCN Newswire) - Eisai Co., Ltd. announced today that the Company had received approval for a new oral jelly formulation of Aricept(R) (donepezil hydrochloride) for the treatment of Alzheimer's disease from the Japanese Ministry of Health, Labour and Welfare. The new oral jelly formulation is easier for patients with Alzheimer's disease who have difficulty swallowing to take and is the first treatment of its kind in the world.